Ihe dị mkpa anyị nyere bụ na ọgwụgwọ nhapụ na-adịgide adịgide na-ejikọta uru nke chemotherapy na immunotherapy, na nke mbụ, ejikọtara ha abụọ ma tinye ya na ọgwụgwọ intratumoral site na ntinye aka. Ọ na-ejikọta ọgwụgwọ mpaghara na nke zuru ụwa ọnụ, ma na-abawanye ntinye na oge nke ọgwụ ọjọọ site na ntọhapụ ọgwụ na-adịgide adịgide n'ime ụbụrụ ahụ, nke na-abụghị nanị na-arụ ọrụ anticancer nke mpaghara nke ọgwụ chemotherapy, ma na-eburukwa n'uche ọrụ nke immunotherapy systemic, si otú ahụ na-eme ka adịghị ike nke ọgwụgwọ ndị ọzọ, na-enye echiche ọhụrụ na ụzọ maka ọgwụgwọ ọrịa cancer, karịsịa maka etiti etiti na elu etuto ahụ, karịsịa maka ibelata na ụbụrụ nlọghachi azụ. na-egbochi tumor Nyefe nwere uru dị oke mkpa; Usoro ọgwụgwọ UMPIC nwere uru nke iji etuto dị ka isi iyi antigen na ọgwụ mgbochi autologous, nke dabara na usoro mmepe nke ọgwụ ahaziri onwe ya. Na etinyere ya na ụlọ ọgwụ, hapten jikọtara ya na ọgwụ chemotherapy maka ọgwụgwọ ntọhapụ na-adịgide adịgide nke ọrịa cancer pancreatic bụ isi na-elekwasị anya, ebe ọ na-ebute mmetụta dị anya, ihe bụ isi ya bụ ime ka mmeghachi omume mgbochi, CD4, CD8, DC, T na cell T na NK, na B-cell metụtara tumor autoantibodies: Antibodies to P53, P16, C16, C, P16, P53, P16, C, P53, C, P16, C, P53, P16, P16, P53, P16, C, P53, C, P53, C, P16, P53, C, P53, C, P16, P53, P16, P53, P16, 2, P53, 16, 53, 16. IMP1, Koc, Survivin, p62, HCC1 na ndị ọzọ oncogenes, nke a bụ nke mbụ na-achọpụta na T na B na-etinye aka na dịghịzi nzaghachi, na-adakarị ọrụ nke distal mmetụta na nke a ọgwụgwọ ahọrọla maka "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Nnwale) (mbipụta nke asaa) nke Chinese National Center nke Anti-Formal Medical Center kwadoro site na ụlọ ọgwụ. Radiology na Therapy, na National Interventional Medicine Innovation Alliance ka ebipụtara na Journal of Clinical Radiology, olu 43, nọmba 19, 2024, 1636-1648.